Statistical Analysis of Veterinary Clinical Trials: Common Methods and Misconceptions

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Pre-specification is paramount: The primary statistical analysis plan, including the primary outcome and statistical tests, must be defined in the trial protocol before data collection commences to prevent bias and p-hacking.
• Effect sizes and confidence intervals are essential: Report effect sizes (e.g., mean difference, risk ratio) with their corresponding confidence intervals, not solely P-values, to convey both the magnitude and precision of treatment effects, especially crucial for underpowered veterinary trials.
• Unit of analysis must align with randomization: The statistical unit of analysis must match the unit at which randomization occurred (e.g., individual animal, herd) to avoid unit-of-analysis errors, which can lead to artificially narrow confidence intervals and inflated significance.
• Address heterogeneity and missing data proactively: Quantify statistical heterogeneity (e.g., using I² statistics) in meta-analyses and pre-specify strategies for handling missing data (e.g., multiple imputation) to ensure robust and unbiased results.
• Adhere to reporting standards: Utilize guidelines such as CONSORT for general trials, REFLECT for livestock, and ARRIVE for animal research to ensure transparency, reproducibility, and proper reporting of statistical methods and results.
• Misinterpretations of P-values and significance are common: A P-value > 0.05 does not prove no effect, and a P-value < 0.05 does not automatically imply clinical relevance; effect sizes and confidence intervals are critical for accurate interpretation.

Veterinary clinical trials generate data that inform treatment decisions across species, from companion animals to production livestock. The statistical methods chosen to analyze these data determine whether conclusions withstand scrutiny, yet trial reports frequently contain analytical errors that compromise their validity. This article reviews the statistical techniques most commonly applied in veterinary clinical trials, the assumptions that underlie them, and the misconceptions that lead investigators astray. It is written for veterinary researchers who design trials, analyze their own data, or critically appraise the literature.

The reader will find a practical framework for selecting analytical approaches, interpreting effect estimates, and recognizing common analytical pitfalls. The scope covers conventional frequentist methods, including hypothesis testing, regression modeling, and survival analysis, with attention to the specific challenges posed by veterinary data structures such as clustering, small sample sizes, and heterogeneous populations. Advanced modeling approaches, including complex hierarchical Bayesian methods, are addressed in a companion article on implementing Bayesian methods in veterinary clinical trials.

At a Glance

The Role of Statistical Inference in Veterinary Trials

Statistical inference in clinical trials serves a specific purpose: to quantify the uncertainty in estimates derived from a sample and to determine whether observed differences plausibly reflect true effects instead of sampling variation. The randomised controlled trial design provides the foundation for causal inference because random allocation balances, on average, both measured and unmeasured confounders between treatment groups. This logic holds in veterinary medicine as it does in human medicine, though veterinary trials face additional constraints.

Veterinary patients are heterogeneous in species, breed, body size, age, and physiological status. A treatment effect observed in a population of laboratory beagles may not generalize to client-owned dogs of diverse breeds, and effects in one species cannot be assumed to transfer to another. Cross-species extrapolation of efficacy data is particularly hazardous in oncology, where pre-clinical animal models have shown poor predictive value for human toxicities in phase 1 trials, with median positive predictive values of 0.65 and negative predictive values of 0.50. The reverse direction, extrapolating from human data to veterinary patients, carries analogous risks. Statistical methods cannot correct for an unrepresentative study population, they can only quantify uncertainty within the population actually sampled.

Hypothesis Testing and the P Value

The conventional frequentist framework tests a null hypothesis, typically that no difference exists between treatment groups, and computes a P value: the probability of observing data at least as extreme as those collected, assuming the null hypothesis is true. A small P value leads to rejection of the null hypothesis and declaration of a statistically significant effect.

The limitations of this framework are well documented. The P value conflates effect size with precision, a trivial difference can achieve statistical significance in a large sample, while a clinically important difference can fail to reach significance in a small one. Moreover, the P value does not answer the question clinicians actually ask: given the observed data, what is the probability that the treatment works? That question belongs to the Bayesian framework, which integrates traditional statistical analysis with predictive inference that more closely mirrors clinical reasoning.

Veterinary trials are frequently underpowered because of practical constraints on case recruitment, and underpowered trials produce unstable P values. A non-significant result in such a trial should be reported as an inconclusive estimate with a confidence interval, not as evidence of equivalence. Conversely, a significant P value in a large trial may reflect a difference too small to matter clinically. The confidence interval around the effect estimate communicates both the magnitude and the precision of the effect, and it should accompany every reported P value.

Effect Size and Confidence Intervals

Effect sizes standardize the magnitude of a treatment effect so that results can be compared across studies and pooled in meta-analysis. Common measures include the mean difference for continuous outcomes, risk ratios and odds ratios for binary outcomes, and standardized mean differences when outcomes are measured on different scales. A systematic review of plant versus animal protein effects on muscle mass, for example, pooled standardized mean differences across 30 randomised trials to estimate a pooled effect of -0.20 with a 95% confidence interval from -0.37 to -0.03, a result that would have been difficult to interpret from individual trial P values alone.

Confidence intervals provide a range of plausible values for the true effect, given the observed data and the assumptions of the statistical model. A 95% confidence interval means that, under repeated sampling, 95% of intervals constructed this way would contain the true parameter. It does not mean there is a 95% probability that the true effect lies within the observed interval, a distinction that is frequently misunderstood. Wider intervals indicate greater uncertainty and should prompt caution in clinical interpretation.

Statistical Heterogeneity and Meta-Analysis

Meta-analysis combines results from multiple trials to produce a pooled estimate with increased precision. The validity of the pooled estimate depends on the degree of statistical heterogeneity, the variability in true treatment effects across studies. The I² statistic describes the percentage of total variation across studies attributable to heterogeneity instead of chance. An I² of 70% or greater suggests substantial heterogeneity that warrants investigation through subgroup analysis or meta-regression, as demonstrated in systematic reviews that report I² statistics to test for statistical heterogeneity.

Random-effects models incorporate between-study variance into the pooled estimate and are generally preferred when heterogeneity is anticipated. Fixed-effect models assume a single true effect across all studies, an assumption rarely justified in veterinary medicine where trials differ in species, breed, disease severity, and outcome definitions. The choice between models should be made before analysis and justified in the protocol.

Choosing the Correct Statistical Test

The selection of a statistical test follows a structured sequence. First, define the primary outcome and its measurement scale. Second, determine how many groups are compared and whether they are independent or paired. Third, assess whether the data satisfy the assumptions of parametric methods. Fourth, decide whether the analysis is univariable or multivariable.

Outcome scales in veterinary trials are typically continuous, binary, ordinal, or time-to-event. Continuous outcomes such as body weight, temperature, or laboratory values permit the widest range of analytic options. Binary outcomes such as survival to discharge or presence of a lesion require methods based on proportions. Ordinal outcomes such as body condition scores or lameness grades require methods that respect the ordering of categories without assuming equal spacing between them. Time-to-event outcomes such as time to recurrence or time to resolution require survival analysis.

The table below summarizes common tests and their appropriate scenarios. The choice between parametric and nonparametric methods depends on sample size, normality of the distribution, and homogeneity of variance. When assumptions are violated, the nonparametric alternative is usually acceptable, though it carries a loss of power.

The t test and ANOVA compare means. The Mann-Whitney U test and Kruskal-Wallis test compare distributions or medians. The chi-square test compares proportions across categories. Fisher exact test is preferred when expected cell counts are low, typically below five. McNemar test handles paired binary data, such as before and after treatment in the same animal.

Multivariable methods adjust for confounding and effect modification. Logistic regression models binary outcomes, linear regression models continuous outcomes, and Cox regression models time-to-event outcomes. These methods require careful attention to the number of events per predictor variable. A common rule of thumb is at least ten events per predictor for logistic and Cox models, though this threshold is debated in the literature.

Species and production system alter the analytic approach. Herd-level outcomes in food animal trials often require cluster-randomised designs and mixed-effects models that account for within-herd correlation. Companion animal trials typically enrol individual animals, but repeated measurements from the same animal over time still require correlated data methods. Equine trials frequently have small sample sizes, which may force the use of nonparametric methods or exact tests.

Common Misconceptions in Veterinary Trial Statistics

Several misconceptions recur in veterinary research. The first concerns the meaning of statistical significance. A p value below 0.05 indicates that the observed result, or one more extreme, would occur less than 5% of the time if the null hypothesis were true. It does not indicate the probability that the null hypothesis is correct, nor does it measure the clinical importance of the effect. The limitations of p values in interpreting clinical results have been described in the context of endometriosis research, where authors argue that Bayesian inference offers a complementary approach that is predictive and sequential, more closely resembling clinical reasoning.

The second misconception is that a non-significant result proves no effect. A trial may be underpowered to detect a clinically meaningful difference. Confidence intervals are more informative than p values alone because they show the range of plausible effect sizes. If the confidence interval includes the null value but is wide, the result is inconclusive instead of negative.

The third misconception is that statistical significance implies clinical relevance. A large sample can produce a statistically significant difference that is too small to matter in practice. Conversely, a clinically important effect may fail to reach significance in a small trial. Effect sizes and confidence intervals should be reported alongside p values.

The fourth misconception is that all data can be analyzed with parametric methods regardless of distribution. Applying a t test to heavily skewed data can produce misleading results. Transformation, nonparametric methods, or robust methods should be considered when assumptions are violated.

The fifth misconception concerns multiple testing. Conducting many statistical tests inflates the family-wise error rate. If twenty independent tests are performed at the 0.05 level, the probability of at least one false positive approaches 64%. Correction methods such as Bonferroni or Benjamini-Hochberg adjustments should be applied, or the analysis should be pre-specified to limit the number of primary comparisons.

The sixth misconception is that heterogeneity in meta-analysis is always a flaw. Some heterogeneity is expected when trials differ in populations, interventions, or outcome definitions. The I-squared statistic quantifies the percentage of total variation attributable to between-study heterogeneity instead of chance. High heterogeneity should prompt exploration of its sources through subgroup analysis or meta-regression, not automatic dismissal of the pooled estimate.

Reporting Standards and Transparency

Reporting guidelines provide a structured framework for describing trial methods and results. The EQUATOR Network maintains a comprehensive library of reporting guidelines, including CONSORT for randomised trials, PRISMA for systematic reviews, and STROBE for observational studies. For veterinary trials specifically, the REFLECT statement addresses the unique features of livestock trials, including herd-level randomisation and production outcomes.

The ARRIVE guidelines specify the minimum information required for transparent and reproducible animal research publications. These guidelines cover sample size calculation, randomisation procedures, blinding, and statistical methods. Adherence to reporting standards allows readers to assess the validity of the analysis and to replicate the study.

Poor reporting of statistical methods is a persistent problem. Many publications omit the software version, the specific test used, or the method for handling missing data. The statistical analysis section should state the primary outcome, the analysis population, the tests applied to each outcome, and the threshold for significance. Pre-registration of the analysis plan reduces the risk of selective reporting and p-hacking.

Practical Considerations in Analysis

Missing data are inevitable in veterinary trials. Animals may die, withdraw, or miss scheduled assessments. The method for handling missing data should be specified in advance. Complete-case analysis is simple but can introduce bias if missingness is related to outcome. Multiple imputation and mixed-effects models that accommodate unbalanced data are preferable when missingness is substantial.

Outliers require careful handling. A single extreme value can dominate a small sample analysis. Outliers should be investigated for data entry errors or biological plausibility before exclusion. Sensitivity analyzes that include and exclude outliers help determine whether conclusions are robust.

The choice between intention-to-treat and per-protocol analysis affects the interpretation of results. Intention-to-treat analysis includes all randomised animals regardless of protocol adherence and preserves the benefit of randomisation. Per-protocol analysis includes only animals that completed the trial as specified and may overestimate treatment effects. The primary analysis should follow the intention-to-treat principle, with per-protocol analysis as a sensitivity check.

Documentation of Statistical Work

Statistical analysis should be documented with the same rigour as clinical procedures. The analysis plan, data dictionary, and analytic code should be archived. Version control for code and data files prevents confusion when analyzes are updated. The final report should include the software and version used, the exact tests performed, and the output for each primary and secondary outcome.

Reproducibility requires that another researcher can obtain the same results from the raw data. This demands clear documentation of data cleaning steps, variable transformations, and exclusion criteria. The ARRIVE guidelines emphasize the importance of reporting these details to enable replication.

Recognized Complications and Failure Modes

Every statistical approach used in veterinary clinical trials carries identifiable failure modes. The most common is the pre-specification failure, where the analysis plan changes after outcome data are inspected. This inflates the type I error rate because the analysis is effectively selected to produce a significant result. Detection depends on comparing the registered protocol with the final manuscript. The EQUATOR Network reporting guidelines require that any deviation from the pre-specified analysis be disclosed with justification.

A second failure mode is the unit-of-analysis error. Animals housed together are not statistically independent, yet many trials analyze individual animals as though they were. This produces artificially narrow confidence intervals and small p values. The discriminating check is to ask whether the intervention was assigned at the group level, the pen level, or the individual level. If assignment was at the group level, the analysis must account for clustering.

A third failure mode is the composite outcome that mixes endpoints of different clinical importance. A composite of death, recurrence, and a laboratory value change can be dominated by the least important component. The corrective action is to report each component separately and to pre-specify the weighting scheme.

A fourth failure mode is the post hoc subgroup analysis. Subgroup findings that were not hypothesised before the trial are frequently overinterpreted. The ARRIVE guidelines for reporting animal research emphasize that subgroup analyzes should be declared as exploratory and interpreted with corresponding caution.

Common Errors and Corrective Actions

Less experienced analysts frequently choose a test based on the distribution of the data instead of the question being asked. Normality testing followed by a switch between parametric and nonparametric tests is a common workflow, but it inflates the type I error rate because the test selection itself is data dependent. The corrective action is to pre-specify the primary analysis and use the normality assessment only as a sensitivity check.

A second error is the interpretation of a non-significant p value as evidence of equivalence. Absence of evidence is not evidence of absence. The corrective action is to pre-specify an equivalence margin and report the confidence interval for the treatment difference. If the interval excludes the margin, equivalence is supported.

A third error is the use of stepwise variable selection in regression models without external validation. Stepwise procedures produce coefficients that are biased away from zero and standard errors that are too small. The corrective action is to limit the number of candidate predictors, use penalised methods where appropriate, and validate the model on an independent dataset.

A fourth error is the failure to distinguish between statistical significance and clinical relevance. A large trial can produce a highly significant p value for a treatment effect that is too small to matter in practice. The corrective action is to report the effect size with its confidence interval and to interpret it against a pre-specified clinically meaningful threshold.

Limitations of the Current Evidence

The veterinary clinical trial evidence base is thinner than the human equivalent. Many veterinary trials are small, single-center, and short in duration. The predictive value of preclinical animal models for human outcomes is itself limited, as demonstrated in oncology where animal toxicity findings showed only moderate positive predictive value for human phase 1 toxicities preclinical toxicity correlation in phase 1 oncology trials. This finding should temper confidence in cross-species extrapolation in both directions.

Expert opinion still differs on several points. The role of Bayesian inference remains contested. Some authors argue that Bayesian methods are more compatible with clinical reasoning because they are predictive and sequential Bayesian inference in endometriosis evidence review, while others maintain that frequentist methods are more familiar to regulators and reviewers. The choice between fixed-effect and random-effects meta-analysis models also generates disagreement, particularly when heterogeneity is moderate and the number of studies is small.

Species-specific guidance varies. The MSD Veterinary Manual provides clinical context for species differences, but statistical reporting standards do not differ by species. The WOAH terrestrial animal health standards address surveillance and trade-related data, which have their own statistical conventions that differ from those of therapeutic trials.

Referral, Consultation, and Reporting

Statistician involvement is warranted when the trial uses clustered randomisation, adaptive designs, missing data imputation, or survival analysis. A veterinary researcher who is not confident in the planned analysis should consult a statistician before data collection begins, not after the data are complete. Laboratory involvement is warranted when outcome measures require specialised assays or when biomarker data need normalization across batches.

Regulatory reporting obligations vary by jurisdiction and species. Adverse events that are unexpected, serious, or suspected to be treatment related should be reported according to the applicable national authority. The AVMA professional practice resources provide guidance on professional obligations, but the specific reporting pathway depends on the product type and the jurisdiction. When in doubt, the researcher should contact the relevant regulatory body directly.

Frequently Asked Questions

How Should I Handle Statistical Analysis When the Trial Budget Cannot Support a Professional Biostatistician?

Engage the statistician before data collection begins, even for a limited number of consultation hours. Many institutions offer statistical support through graduate programs or collaborative cores at reduced cost. If no support is available, restrict the analysis plan to methods you can implement and interpret correctly, such as two-sample tests, chi-square tests, and basic regression. Avoid complex modeling you cannot validate. Use the EQUATOR Network reporting guidelines to structure the methods section so reviewers can assess what was actually done. Document every analytical decision, including software versions and syntax, so a statistician can audit the work later.

What Should I Do When the Planned Sample Size Cannot Be Achieved?

Recruit as many animals as feasible, then report the achieved power retrospectively using the observed effect size and variance. This calculation describes the sensitivity of the completed study, it does not rescue an underpowered design. Consider whether a multi-site collaboration could pool resources, or whether the question can be reframed as a pilot study with explicit hypothesis-generating goals. Pre-specify the minimum detectable effect for the sample size actually obtained. The ARRIVE guidelines require transparent reporting of sample size determination and any deviations from the original plan, which preserves the scientific value of the work even when recruitment falls short.

How Do I Choose Between Parametric and Nonparametric Tests for Small Animal Samples?

For sample sizes below approximately 10 per group, normality tests lack power to detect departures from the normal distribution. Examine histograms and quantile-quantile plots directly, and consider whether the measurement scale produces bounded or skewed data, which is common for clinical scores and lesion grades. When normality is doubtful, use the nonparametric analogue, such as the Wilcoxon rank-sum test instead of the two-sample t test. The cost in power is modest, often 5 to 10 percent, and the protection against inflated type I error is substantial. Report medians with interquartile ranges for nonparametric analyzes instead of means with standard deviations.

What Are the Minimum Data Management Practices Required for a Defensible Veterinary Trial?

Maintain a prospective log of every animal screened, enrolled, and withdrawn, with reasons for each exclusion. Store source data in a locked, version-controlled database with a complete audit trail. Define all variables in a data dictionary before analysis begins, including units, coding schemes, and missing value conventions. Record the date and time of every data entry and any subsequent correction. The MSD Veterinary Manual and other professional references emphasize that traceability from the medical record to the analysis dataset is the foundation of credible research. A second individual should independently verify a random sample of entries against source records, and the verification results should be retained with the study files.

How Should I Explain Statistical Uncertainty to a Client or Practice Owner Who Wants a Definite Answer?

Frame the result as a range of plausible effects instead of a single yes or no. State the observed effect size and its confidence interval in clinical terms, for example, the treatment reduced recurrence from 40 percent to 25 percent, with the true reduction likely between 10 and 20 percentage points. Explain that the confidence interval reflects the information contained in the study, not the quality of the clinical care provided. Acknowledge that individual animals may respond differently and that the interval does not guarantee the outcome for any particular patient. The AVMA practice resources provide communication frameworks that support shared decision-making under uncertainty.

When Should I Seek External Statistical Review Before Submitting a Manuscript?

Seek review whenever the analysis involves more than simple descriptive statistics and a single primary comparison. External review is also indicated when the trial used adaptive elements, when multiple imputation or other missing data methods were applied, or when the results are borderline and the interpretation depends heavily on analytical choices. A reviewer who was not involved in the study can identify unconscious assumptions in the analysis plan. The WOAH terrestrial animal health standards and journal requirements increasingly expect evidence of statistical review for clinical research. Budget for this review as a line item in the grant proposal, because post hoc review after rejection is more expensive and delays dissemination.

Related Clinical & Scientific Guides

• Conducting Systematic Reviews of Veterinary Diagnostic Test Accuracy
• Bias in Veterinary Research: Types, Sources, and Mitigation
• Cluster Randomized Trials in Veterinary Research: Design and Analysis

References and Further Reading

• Effect of Plant Versus Animal Protein on Muscle Mass, Strength, Physical Performance, and Sarcopenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.. 2025.
• Reconsidering evidence-based management of endometriosis.. 2022.
• Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials.. 2020.
• Single-trial multiwavelet coherence in application to neurophysiological time series.. 2007.
• Association Between Triglyceride-Glucose Index and Breast Cancer: A Systematic Review and Meta-Analysis.. 2025.
• Does Stepwise Voltage Ramping Protect the Kidney from Injury During Extracorporeal Shockwave Lithotripsy? Results of a Prospective Randomized Trial.. 2016.
• ARRIVE Guidelines 2.0 for Reporting Animal Research. PLOS Biology, 2020.
• EQUATOR Network Reporting Guidelines. EQUATOR Network.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• Implementing Bayesian Methods in Veterinary Clinical Trials
• Randomization and Allocation Concealment in Veterinary Clinical Trials
• Blinding in Veterinary Clinical Research: Methods and Challenges
• Outcome Measures in Veterinary Clinical Trials: Selection and Validation
• Selecting and Implementing Blinding Methods in Veterinary Trials

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.